Skip to main content
Erschienen in: Diabetologia 6/2022

11.03.2022 | Article

Diabetes, GDF-15 and incident heart failure: the atherosclerosis risk in communities study

verfasst von: Justin B. Echouffo-Tcheugui, Natalie Daya, Chiadi E. Ndumele, Kunihiro Matsushita, Ron C. Hoogeveen, Christie M. Ballantyne, Josef Coresh, Amil M. Shah, Elizabeth Selvin

Erschienen in: Diabetologia | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Elevated circulating growth differentiation factor-15 (GDF-15), a marker of cellular stress, is associated with both heart failure (HF) and diabetes. However, it is unclear to what extent GDF-15 is associated with HF among individuals with and without diabetes.

Methods

We evaluated 10,570 participants free of HF at Visit 3 (1993–1995) of the Atherosclerosis Risk in Communities study. We used Cox regression to evaluate the joint associations of GDF-15 and diabetes with incident HF. Models were adjusted for traditional cardiovascular risk factors.

Results

Among a total of 10,570 individuals (mean age of 60.0 years, 54% women, 27% black adults), elevated GDF-15 (≥75th percentile) was more common in people with diabetes compared with those without diabetes (32.8% vs 23.6%, p<0.0001). During 23 years of follow-up, there were 2429 incident HF events. GDF-15 (in quartiles) was independently associated with HF among those with and without diabetes, with a stronger association among individuals with diabetes (p-for-diabetes–GDF-15 interaction = 0.034): HR for highest vs lowest GDF-15 quartile (reference): 1.64 (95% CI 1.41, 1.91) among those without diabetes and 1.72 (95% CI 1.32, 2.23) among those with diabetes. Individuals with diabetes and elevated GDF-15 had the highest risk of incident HF (HR 2.46; 95% CI 1.99, 3.03). After accounting for HF risk factors, GDF-15 provided additional prognostic information among participants with diabetes (ΔC statistic for model with vs model without GDF-15: +0.008, p = 0.001) and among those without diabetes (+0.006, p<0.0001).

Conclusions/interpretation

In a community-based sample of US adults, GDF-15 provided complementary prognostic information on the HF risk, especially among individuals with diabetes.

Graphical abstract

Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Bootcov MR, Bauskin AR, Valenzuela SM et al (1997) MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A 94:11514–11519PubMedPubMedCentralCrossRef Bootcov MR, Bauskin AR, Valenzuela SM et al (1997) MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A 94:11514–11519PubMedPubMedCentralCrossRef
2.
Zurück zum Zitat Unsicker K, Spittau B, Krieglstein K (2013) The multiple facets of the TGF-β family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. Cytokine Growth Factor Rev 24:373–384PubMedCrossRef Unsicker K, Spittau B, Krieglstein K (2013) The multiple facets of the TGF-β family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. Cytokine Growth Factor Rev 24:373–384PubMedCrossRef
3.
Zurück zum Zitat Macia L, Tsai VWW, Nguyen AD et al (2012) Macrophage inhibitory cytokine 1 (MIC-1/GDF15) decreases food intake, body weight and improves glucose tolerance in mice on normal & obesogenic diets. PLoS One 7:e34868PubMedPubMedCentralCrossRef Macia L, Tsai VWW, Nguyen AD et al (2012) Macrophage inhibitory cytokine 1 (MIC-1/GDF15) decreases food intake, body weight and improves glucose tolerance in mice on normal & obesogenic diets. PLoS One 7:e34868PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat Wang X, Chrysovergis K, Kosak J et al (2014) hNAG-1 increases lifespan by regulating energy metabolism and insulin/IGF-1/mTOR signaling. Aging (Albany NY) 6:690–704CrossRef Wang X, Chrysovergis K, Kosak J et al (2014) hNAG-1 increases lifespan by regulating energy metabolism and insulin/IGF-1/mTOR signaling. Aging (Albany NY) 6:690–704CrossRef
5.
Zurück zum Zitat Chrysovergis K, Wang X, Kosak J et al (2014) NAG-1/GDF-15 prevents obesity by increasing thermogenesis, lipolysis and oxidative metabolism. Int J Obes 38:1555–1564CrossRef Chrysovergis K, Wang X, Kosak J et al (2014) NAG-1/GDF-15 prevents obesity by increasing thermogenesis, lipolysis and oxidative metabolism. Int J Obes 38:1555–1564CrossRef
6.
Zurück zum Zitat Ohkuma T, Komorita Y, Peters SAE, Woodward M (2019) Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals. Diabetologia 62:1550–1560PubMedPubMedCentralCrossRef Ohkuma T, Komorita Y, Peters SAE, Woodward M (2019) Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals. Diabetologia 62:1550–1560PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Bao X, Borné Y, Muhammad IF et al (2019) Growth differentiation factor 15 is positively associated with incidence of diabetes mellitus: the Malmö diet and Cancer–cardiovascular cohort. Diabetologia 62:78–86PubMedCrossRef Bao X, Borné Y, Muhammad IF et al (2019) Growth differentiation factor 15 is positively associated with incidence of diabetes mellitus: the Malmö diet and Cancer–cardiovascular cohort. Diabetologia 62:78–86PubMedCrossRef
8.
Zurück zum Zitat Kempf T, Guba-Quint A, Torgerson J, Magnone MC, Haefliger C, Bobadilla M, Wollert K (2012) Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in obese nondiabetic individuals: results from the XENDOS trial. Eur J Endocrinol 162:913–917 Kempf T, Guba-Quint A, Torgerson J, Magnone MC, Haefliger C, Bobadilla M, Wollert K (2012) Growth differentiation factor 15 predicts future insulin resistance and impaired glucose control in obese nondiabetic individuals: results from the XENDOS trial. Eur J Endocrinol 162:913–917
9.
Zurück zum Zitat Wang TJ, Wollert KC, Larson MG et al (2012) Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham heart study. Circulation 126:1596–1604PubMedCrossRef Wang TJ, Wollert KC, Larson MG et al (2012) Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham heart study. Circulation 126:1596–1604PubMedCrossRef
10.
Zurück zum Zitat Stenemo M, Nowak C, Byberg L et al (2018) Circulating proteins as predictors of incident heart failure in the elderly. Eur J Heart Fail 20:55–62PubMedCrossRef Stenemo M, Nowak C, Byberg L et al (2018) Circulating proteins as predictors of incident heart failure in the elderly. Eur J Heart Fail 20:55–62PubMedCrossRef
11.
Zurück zum Zitat Fluschnik N, Ojeda F, Zeller T et al (2018) Predictive value of long-term changes of growth differentiation factor-15 over a 27-year-period for heart failure and death due to coronary heart disease. PLoS One 13:e0197497PubMedPubMedCentralCrossRef Fluschnik N, Ojeda F, Zeller T et al (2018) Predictive value of long-term changes of growth differentiation factor-15 over a 27-year-period for heart failure and death due to coronary heart disease. PLoS One 13:e0197497PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Bansal N, Zelnick L, Go A et al (2019) Cardiac biomarkers and risk of incident heart failure in chronic kidney disease: the CRIC (chronic renal insufficiency cohort) study. J Am Heart Assoc 8:e012336PubMedPubMedCentralCrossRef Bansal N, Zelnick L, Go A et al (2019) Cardiac biomarkers and risk of incident heart failure in chronic kidney disease: the CRIC (chronic renal insufficiency cohort) study. J Am Heart Assoc 8:e012336PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Kempf T, von Haehling S, Peter T et al (2007) Prognostic utility of growth differentiation Factor-15 in patients with chronic heart failure. J Am Coll Cardiol 50:1054–1060PubMedCrossRef Kempf T, von Haehling S, Peter T et al (2007) Prognostic utility of growth differentiation Factor-15 in patients with chronic heart failure. J Am Coll Cardiol 50:1054–1060PubMedCrossRef
14.
Zurück zum Zitat Anand IS, Kempf T, Rector TS et al (2010) Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the valsartan heart failure trial. Circulation 122:1387–1395PubMedCrossRef Anand IS, Kempf T, Rector TS et al (2010) Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the valsartan heart failure trial. Circulation 122:1387–1395PubMedCrossRef
15.
Zurück zum Zitat Cotter G, Voors AA, Prescott MF et al (2015) Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study. Eur J Heart Fail 17:1133–1143PubMedCrossRef Cotter G, Voors AA, Prescott MF et al (2015) Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study. Eur J Heart Fail 17:1133–1143PubMedCrossRef
16.
Zurück zum Zitat Fujita Y, Taniguchi Y, Shinkai S, Tanaka M, Ito M (2016) Secreted growth differentiation factor 15 as a potential biomarker for mitochondrial dysfunctions in aging and age-related disorders. Geriatr Gerontol Int 16(Suppl 1):17–29PubMedCrossRef Fujita Y, Taniguchi Y, Shinkai S, Tanaka M, Ito M (2016) Secreted growth differentiation factor 15 as a potential biomarker for mitochondrial dysfunctions in aging and age-related disorders. Geriatr Gerontol Int 16(Suppl 1):17–29PubMedCrossRef
17.
Zurück zum Zitat Ji X, Zhao L, Ji K et al (2017) Growth differentiation factor 15 is a novel diagnostic biomarker of mitochondrial diseases. Mol Neurobiol 54:8110–8116PubMedCrossRef Ji X, Zhao L, Ji K et al (2017) Growth differentiation factor 15 is a novel diagnostic biomarker of mitochondrial diseases. Mol Neurobiol 54:8110–8116PubMedCrossRef
18.
Zurück zum Zitat Kalko SG, Paco S, Jou C et al (2014) Transcriptomic profiling of TK2 deficient human skeletal muscle suggests a role for the p53 signalling pathway and identifies growth and differentiation factor-15 as a potential novel biomarker for mitochondrial myopathies. BMC Genomics 15:91PubMedPubMedCentralCrossRef Kalko SG, Paco S, Jou C et al (2014) Transcriptomic profiling of TK2 deficient human skeletal muscle suggests a role for the p53 signalling pathway and identifies growth and differentiation factor-15 as a potential novel biomarker for mitochondrial myopathies. BMC Genomics 15:91PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Pinti MV, Fink GK, Hathaway QA, Durr AJ, Kunovac A, Hollander JM (2019) Mitochondrial dysfunction in type 2 diabetes mellitus: an organ-based analysis. Am J Physiol Endocrinol Metab 316:E268–E285PubMedPubMedCentralCrossRef Pinti MV, Fink GK, Hathaway QA, Durr AJ, Kunovac A, Hollander JM (2019) Mitochondrial dysfunction in type 2 diabetes mellitus: an organ-based analysis. Am J Physiol Endocrinol Metab 316:E268–E285PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Scheuermann-Freestone M, Madsen PL, Manners D et al (2003) Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation. 107:3040–3046PubMedCrossRef Scheuermann-Freestone M, Madsen PL, Manners D et al (2003) Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes. Circulation. 107:3040–3046PubMedCrossRef
21.
Zurück zum Zitat Levelt E, Rodgers CT, Clarke WT et al (2016) Cardiac energetics, oxygenation, and perfusion during increased workload in patients with type 2 diabetes mellitus. Eur Heart J 37:3461–3469PubMedCrossRef Levelt E, Rodgers CT, Clarke WT et al (2016) Cardiac energetics, oxygenation, and perfusion during increased workload in patients with type 2 diabetes mellitus. Eur Heart J 37:3461–3469PubMedCrossRef
22.
Zurück zum Zitat Anderson EJ, Rodriguez E, Anderson CA, Thayne K, Chitwood WR, Kypson AP (2011) Increased propensity for cell death in diabetic human heart is mediated by mitochondrial-dependent pathways. Am J Physiol Heart Circ Physiol 300:H118–H124PubMedCrossRef Anderson EJ, Rodriguez E, Anderson CA, Thayne K, Chitwood WR, Kypson AP (2011) Increased propensity for cell death in diabetic human heart is mediated by mitochondrial-dependent pathways. Am J Physiol Heart Circ Physiol 300:H118–H124PubMedCrossRef
23.
Zurück zum Zitat Rijzewijk LJ, van der Meer RW, Lamb HJ et al (2009) Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol 54:1524–1532PubMedCrossRef Rijzewijk LJ, van der Meer RW, Lamb HJ et al (2009) Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol 54:1524–1532PubMedCrossRef
24.
Zurück zum Zitat The ARIC Investigators (1989) The atherosclerosis risk in communities (ARIC) study: design and objectives. Am J Epidemiol 129:687–702CrossRef The ARIC Investigators (1989) The atherosclerosis risk in communities (ARIC) study: design and objectives. Am J Epidemiol 129:687–702CrossRef
25.
Zurück zum Zitat Tin A, Yu B, Ma J, Masushita K (2019) Reproducibility and variability of protein Analytes measured using a multiplexed modified aptamer assay. J Appl Lab Med 4:30–39PubMedPubMedCentralCrossRef Tin A, Yu B, Ma J, Masushita K (2019) Reproducibility and variability of protein Analytes measured using a multiplexed modified aptamer assay. J Appl Lab Med 4:30–39PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Kim CH, Tworoger SS, Stampfer MJ et al (2018) Stability and reproducibility of proteomic profiles measured with an aptamer-based platform. Sci Rep 8:8382PubMedPubMedCentralCrossRef Kim CH, Tworoger SS, Stampfer MJ et al (2018) Stability and reproducibility of proteomic profiles measured with an aptamer-based platform. Sci Rep 8:8382PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Ganz P, Heidecker B, Hveem K et al (2016) Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA 315:2532–2541PubMedCrossRef Ganz P, Heidecker B, Hveem K et al (2016) Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA 315:2532–2541PubMedCrossRef
30.
31.
Zurück zum Zitat Avery CL, Loehr LR, Baggett C et al (2012) The population burden of heart failure attributable to modifiable risk factors: the ARIC (atherosclerosis risk in communities) study. J Am Coll Cardiol 60:1640–1646PubMedCrossRef Avery CL, Loehr LR, Baggett C et al (2012) The population burden of heart failure attributable to modifiable risk factors: the ARIC (atherosclerosis risk in communities) study. J Am Coll Cardiol 60:1640–1646PubMedCrossRef
32.
Zurück zum Zitat Richardson MT, Ainsworth BE, Wu HC, Jacobs DR Jr, Leon AS (1995) Ability of the atherosclerosis risk in communities (ARIC)/Baecke questionnaire to assess leisure-time physical activity. Int J Epidemiol 24:685–693PubMedCrossRef Richardson MT, Ainsworth BE, Wu HC, Jacobs DR Jr, Leon AS (1995) Ability of the atherosclerosis risk in communities (ARIC)/Baecke questionnaire to assess leisure-time physical activity. Int J Epidemiol 24:685–693PubMedCrossRef
33.
Zurück zum Zitat Piercy KL, Troiano RP, Ballard RM et al (2018) The physical activity guidelines for Americans. JAMA. 320:2020–2028PubMedCrossRef Piercy KL, Troiano RP, Ballard RM et al (2018) The physical activity guidelines for Americans. JAMA. 320:2020–2028PubMedCrossRef
35.
Zurück zum Zitat Coll AP, Chen M, Taskar P et al (2020) GDF15 mediates the effects of metformin on body weight and energy balance. Nature 578:444–448PubMedCrossRef Coll AP, Chen M, Taskar P et al (2020) GDF15 mediates the effects of metformin on body weight and energy balance. Nature 578:444–448PubMedCrossRef
36.
Zurück zum Zitat Vila G, Riedl M, Anderwald C et al (2011) The relationship between insulin resistance and the cardiovascular biomarker growth differentiation factor-15 in obese patients. Clin Chem 57:309–316PubMedCrossRef Vila G, Riedl M, Anderwald C et al (2011) The relationship between insulin resistance and the cardiovascular biomarker growth differentiation factor-15 in obese patients. Clin Chem 57:309–316PubMedCrossRef
37.
Zurück zum Zitat Ho JE, Mahajan A, Chen MH et al (2012) Clinical and genetic correlates of growth differentiation factor 15 in the community. Clin Chem 58:1582–1591PubMedPubMedCentralCrossRef Ho JE, Mahajan A, Chen MH et al (2012) Clinical and genetic correlates of growth differentiation factor 15 in the community. Clin Chem 58:1582–1591PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 393:31–39PubMedCrossRef Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 393:31–39PubMedCrossRef
39.
Zurück zum Zitat Zannad F, Ferreira JP, Pocock SJ et al (2020) SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials. Lancet 396:819–829PubMedCrossRef Zannad F, Ferreira JP, Pocock SJ et al (2020) SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials. Lancet 396:819–829PubMedCrossRef
40.
Zurück zum Zitat Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci 101:671–679CrossRef Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci 101:671–679CrossRef
41.
Zurück zum Zitat Kothari V, Stevens RJ, Adler AI et al (2002) UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK prospective diabetes study risk engine. Stroke. 33:1776–1781PubMedCrossRef Kothari V, Stevens RJ, Adler AI et al (2002) UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK prospective diabetes study risk engine. Stroke. 33:1776–1781PubMedCrossRef
42.
Zurück zum Zitat Schlittenhardt D, Schober A, Strelau J et al (2004) Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions. Cell Tissue Res 318:325–333PubMedCrossRef Schlittenhardt D, Schober A, Strelau J et al (2004) Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions. Cell Tissue Res 318:325–333PubMedCrossRef
43.
Zurück zum Zitat Lok SI, Winkens B, Goldschmeding R et al (2012) Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support. Eur J Heart Fail 14:1249–1256PubMedCrossRef Lok SI, Winkens B, Goldschmeding R et al (2012) Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support. Eur J Heart Fail 14:1249–1256PubMedCrossRef
44.
Zurück zum Zitat Xu J, Kimball TR, Lorenz JN et al (2006) GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 98:342–350PubMedCrossRef Xu J, Kimball TR, Lorenz JN et al (2006) GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 98:342–350PubMedCrossRef
Metadaten
Titel
Diabetes, GDF-15 and incident heart failure: the atherosclerosis risk in communities study
verfasst von
Justin B. Echouffo-Tcheugui
Natalie Daya
Chiadi E. Ndumele
Kunihiro Matsushita
Ron C. Hoogeveen
Christie M. Ballantyne
Josef Coresh
Amil M. Shah
Elizabeth Selvin
Publikationsdatum
11.03.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Diabetologia / Ausgabe 6/2022
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-022-05678-6

Weitere Artikel der Ausgabe 6/2022

Diabetologia 6/2022 Zur Ausgabe

List of Referees

Referees 2021

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.